[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia-alzheimers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia-alzheimers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,88,119,150,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100458152","passive-sensor-identification-of-digital-biomarkers-to-assess-effects-of-orally-administered-nicotinamide-riboside-100458152",false,"NCT05245903","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia","Emerald-NRAD","Inclusion Criteria:\n\n* Ability of the participant and\u002For his\u002Fher legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.\n* Ability to speak and read fluently in English\n* 18-89 years old (inclusive)\n* Normal or corrected to normal hearing and vision\n* Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above\n* Study partner available for duration of trial participation\n* At least one copy of the APOE ε4 allele\n* An aggregate risk score \\> 4 according to the risk analysis method developed by Sabbagh et al. (2017)\n* For individuals who are taking niacin (or a vitamin supplement with niacin) of \\>200mg, the completion of a two-week wash-out period\n\nExclusion Criteria:\n\n* Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician\n* Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician\n* Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician\n* Diagnosis of a mitochondrial disorder\n* Any MRI safety contraindications\n* History of drug hypersensitivity or intolerance to NR\n* Transient ischemic attack or stroke within 1 year prior to screening\n* History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen\n* History of head injury rated as moderate or worse, per DSM-5 criteria\n* History of seizure within prior 10 years\n* Current use of medication with known adverse effects on cognition (benzodiazepines, barbiturates, opiate analgesics, first generation antipsychotic medication, anticholinergics, sedating antihistamines, tricyclic anti-depressants)\n* Change in dose of any psychiatric medications within 4 weeks of screening visit\n* Prior use of L-DOPA, any anti-Parkinsonian medication, or prior treatment with anti-amyloid immunotherapy\n* Current use of putative mitochondrial enhancers or antioxidants (e.g. carnitine, creatine, Co-Q10, N-acetyl cysteine, pramipexole)\n* Initiation of treatment or change in dosing of acetylcholinesterase inhibitors (AChEIs) and memantine within 4 weeks of screening\n* Prior use of prescription narcotics 4 weeks before screening\n* Female subjects who are pregnant or breastfeeding\n* The current use of niacin (or a vitamin supplement with niacin) \\>200mg within the last two weeks prior to study visit","ALL","18 Years","89 Years",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL","This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.",[26,27,28,29,30,31,32,33,34,35],"Alzheimer Disease","Dementia Alzheimers","Dementia","Cognitive Impairment","Mild Cognitive Impairment","Neurodegenerative Diseases","Neurocognitive Disorders","Neurocognitive Dysfunction","Cognitive Dysfunction","Mental Disorder",[37,38,39,30,40],"Passive sensing","Digital phenotyping","Alzheimer's Dementia","Digital biomarker","RECRUITING","2025-11-04",{"date":44,"type":45},"2025-11-06","ACTUAL",{"date":47,"type":45},"2022-05-31",{"date":49,"type":22},"2026-05-31",{"name":51,"class":52},"Mclean Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":23,"phases":4,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":53},"100592421","home-based-brain-monitoring-with-a-garment-eeg-to-study-cognitive-decline-in-the-aging-population-100592421","NCT06993207","HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population","Validation of a Home-use Instrument for the Quantification of Cognitive Function in a Population at Risk of Dementia","Hogar","General Inclusion Criteria:\n\n* Native Spanish speaker.\n* Agree to the examination procedures and tests.\n* Ability to involve a close family member or friend for functional evaluation.\n* Normal or corrected-to-normal color vision.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion.\n* No severe psychiatric (according to DSM-V) or neurological diseases (epilepsy with frequent seizures (\\>1\u002Fmonth) in the last year, multiple sclerosis, etc.).\n* No diseases that may interfere with cognitive functions (renal insufficiency on hemodialysis, liver cirrhosis, chronic pulmonary disease with oxygen therapy, solid organ transplant, fibromyalgia, active cancer under treatment).\n* No severe hearing and\u002For visual impairments, neurodevelopmental, or psychomotor disorders.\n* No brain injuries that may interfere with cognitive functions (history of traumatic brain injury with parenchymal injury or macroscopic ischemic stroke of large extra-axial vessels or hemorrhagic stroke, brain surgery, brain tumors, or other causes that could result in acquired brain damage such as brain chemotherapy or radiotherapy).\n* No treatment with antipsychotic agents in the 6 months prior to the initial assessment.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion. No psychiatric or neurological medication.\n* No alcohol or drug abuse.\n* No serious health problems in the last 12 months (especially neurological or cardiac disorders).\n\nInclusion Criteria 'Mild Dementia' group:\n\n* Diagnosis of Alzheimer's type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Diagnosis of vascular or mixed type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Lack of autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment.\n\nInclusion Criteria 'Mild Cognitive Impairment' group:\n\n* Diagnosis of mild cognitive impairment, based on a clinical and cognitive assessment conducted by a physician.\n* Preserved autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment\n\nInclusion Criteria 'Subjective Cognitive Decline' group:\n\n* Adherence to SCD-I criteria.\n* Attendance at primary care consultation with memory complaints lasting more than 6 months.\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Onset of subjective cognitive decline in the last 5 years.\n* Concerns related to subjective cognitive decline (not associated with an acute event) expressed by the participant and\u002For an informant.\n* Cognitive performance within the normal range on cognitive tests (MMSE (Mini Mental State Exam) \\\u003C 26 \u002F MIS (Memory Impairment Screen) \\\u003C 6).\n* No severe depressive symptoms, indicated by scores \\> 17\\* on the 30-item Geriatric Depression Scale.\n\nInclusion criteria No impairment group:\n\n* Cognitive performance within the normal range on cognitive tests (MMSE \\\u003C 26 \u002F MIS \\\u003C 6).\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Not meeting the criteria for SCD-I \\[21\\].\n* Independent person living in their own home.\n* No subjective memory complaints.",true,"60 Years",{"count":65,"type":22},500,"3 Years","This study will investigate the validity of the HOGAR EEG\u002FPSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive decline. The kit consists of two EEG headbands and a mobile computing device that allows measurements of sleep patterns (PSG) and brain activity (EEG) in a home environment.",[28,30,27,69,70,71],"Dementia, Mixed","Subjective Cognitive Decline","Dementia, Vascular",[28,73,74,75,76,77],"MCI","Memory","cognitive decline","EEG","Sleep EEG","2025-05-19",{"date":80,"type":45},"2025-05-28",{"date":82,"type":45},"2024-01-15",{"date":84,"type":22},"2028-12-31",{"name":86,"class":87},"Bitbrain","INDUSTRY",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":62,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":53},"100555144","language-speech-and-motor-function-in-mci-due-to-ad-and-alzheimers-disease-100555144","NCT06508268","Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease","Language, Speech and Motor Function in Mild Cognitive Impairment Due to AD and Alzheimer's Disease","Inclusion Criteria:\n\nA subject with MCI with a likelihood of underlying AD pathophysiology must meet the following criteria:\n\n* Established diagnosis of MCI due to AD with a likelihood according to NIA-AA criteria (Albert et al., 2011).\n* A score of stage three on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).\n\nA subject with AD must meet the following criteria:\n\n* Established diagnosis of AD (amnestic or non-amnestic) or etiologically mixed presentation of AD according to DSM-5 (American Psychiatric Association, 2013) or NINCDS-ARDRA criteria (Jack et al., 2018; McKann et al., 2011).\n* The following scores on the Global Deterioration Scale (GDS): four for mild AD, five for moderate AD (Reisberg et al., 1982).\n\nAll subjects of the control group must meet the following criteria:\n\n* A score of stage one or two on the Global Deterioration Scale (GDS) (Reisberg et al., 1982).\n* They are age-matched with the MCI due to AD or AD patients included in the study.\n\nAll subjects must meet the following criteria:\n\n* First language is Dutch and\u002For Frisian.\n* Able to walk independently with or without walking aid.\n* Able to squeeze with each hand.\n\nExclusion Criteria:\n\nA subject with MCI due to AD or AD who meets the following criteria will be excluded from participation in this study:\n\n* Having a neurological or neurodegenerative disease or disorder that may be contributing to cognitive impairment above and beyond that caused by AD or mixed AD; Down's syndrome, other subtypes of dementia, autism spectrum disorder.\n* Having an established diagnosis of a psychiatric disorder, e.g. schizophrenia, depression.\n\nAll subjects in the control group who meets following criteria will be excluded from participation in this study:\n\n● Suffers from a neurological, neurodegenerative or psychiatric disease or disorder.\n\nAll subjects in any group who meet any of the following criteria will be excluded from participation in this study:\n\n* Hearing loss (with or without hearing aid) that affects communication.\n* Vision loss (with or without glasses or lenses) that affects communication.\n* History of language problems, speech problems or dyslexia.\n* Suffers from additional disorders or diseases which may limit gait, hand grip strength, language and\u002For speech.\n* Medication use that influence gait, hand grip strength, speech or language performance at time of testing.\n* Being terminally ill (i.e., life expectancy \\< 2 weeks according to the attending physician).",{"count":96,"type":22},208,"The goal of this observational cross-sectional study is to explore the characteristics of language, speech, and motor function in persons with Mild Cognitive Impairment due to Alzheimer's disease (\"MCI due to AD\") and persons with mild and moderate Alzheimer's disease (\"AD\"). This study aims to:\n\n* Explore motor, speech, and language functions in MCI due to AD and mild and moderate AD.\n* Combine the characteristics of motor, language, and speech functions to gain more insight into the association of language, speech, and motor changes during MCI due to AD and mild and moderate AD.\n\nResearchers will compare the outcomes to an age-matched control group without cognitive impairment.\n\nParticipants will undergo:\n\n* Two motor function tests to assess gait and hand grip strength.\n* Four language and speech function tests to assess spontaneous speech and verbal fluency..",[99,100,27],"Alzheimer's Disease","MCI Due to AD",[102,103,104,105,106,107,108,109],"Alzheimer's disease","MCI due to AD","Language","Speech","Motor","Gait","Hand grip strength","Fluency","2024-07-17",{"date":112,"type":45},"2024-07-18",{"date":114,"type":22},"2024-07-12",{"date":116,"type":22},"2025-02-09",{"name":118,"class":52},"Hanze University of Applied Sciences Groningen",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":53},"100453690","blood-based-biomarkers-for-diagnosis-of-alzheimers-100453690","NCT05187819","Blood-based Biomarkers for Diagnosis of Alzheimer's","Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice","Inclusion Criteria:\n\n* Participants suspected by their GP to have possible dementia, based on history, clinical examination and\u002For cognitive screening\n\nExclusion Criteria:\n\n* Lack of capacity for consent as judged by the GP.\n* Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.\n* Patients not wanting to be referred to the memory outpatient clinic.","40 Years","100 Years",{"count":129,"type":22},300,"INTERVENTIONAL",[132],"NA","Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and\u002For positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.\n\nThis project will assess the predictive value of these tests in a general practice population.\n\nThe hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.",[27],[136,137,138,139],"Alzheimer's dementia","Diagnosis","Biomarkers","Clinical practice","2023-09-26",{"date":142,"type":45},"2023-09-28",{"date":144,"type":45},"2023-06-01",{"date":146,"type":22},"2029-12-31",{"name":148,"class":149},"Helse Stavanger HF","OTHER_GOV",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":62,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":23,"phases":4,"briefSummary":163,"conditions":164,"keywords":170,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":53},"100463530","the-dampness-syndrome-of-chinese-medicine-cohort-study-100463530","NCT05315895","The Dampness Syndrome of Chinese Medicine Cohort Study","A Multi-Center Prospective Cohort Study of Dampness Syndrome in China","DACOS","Inclusion Criteria:\n\n1. Residents aged 30 to 79, whose residence is consistent with their registered permanent residence location;\n2. Residents who voluntarily participate in the project, agree to the collection of their biological information, and sign the informed consent form;\n3. Residents who have no mental illness and other related diseases, and display a normal ability of expression and understanding;\n\nExclusion Criteria:\n\n1. Residents who reject collaboration;\n2. Residents who allow no follow-up visits.","35 Years","79 Years",{"count":161,"type":22},100000,"5 Years","The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.",[165,166,27,167,168,169],"Chronic Disease","Cancer","Metabolic Disease","Aging","Alzheimer Disease, Early Onset",[171,172,173],"Dampness Syndrome","multi-center study","prospective cohort study","2022-11-14",{"date":176,"type":45},"2022-11-15",{"date":178,"type":45},"2022-06-06",{"date":180,"type":22},"2028-03-30",{"name":182,"class":52},"Guangzhou University of Traditional Chinese Medicine",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":53},"100441071","pumch-dementia-longitudinal-cohort-study-100441071","NCT05023564","PUMCH Dementia Longitudinal Cohort Study","Peking Union Medical College Hospital (PUMCH) Dementia Longitudinal Cohort Study","Inclusion Criteria:\n\n* Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia\n* Fixed care giver and can follow up regularly\n\nExclusion Criteria:\n\n* Not demented, including MCI\n* Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation\n* Without fixed care giver\n* Reject informed consent\n* Expected life shorter than 2 years",{"count":191,"type":22},20000,"The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.",[28,71,194,69,27,195,196],"Dementia With Lewy Bodies","Dementia Frontal","Dementia, Mild","2022-09-10",{"date":199,"type":45},"2022-09-13",{"date":201,"type":45},"2020-12-01",{"date":203,"type":22},"2040-12-31",{"name":205,"class":52},"Peking Union Medical College Hospital"]